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Letters

that our mention of “interventional therapies”1 encompasses
the broad range of both potential surgical and endovascular
options; our own experience also supports the authors’ observations of beneficial outcomes after surgical revascularization. At our institution, after careful evaluation using the
Vertebrobasilar Flow Evaluation and Risk of Transient
Ischemic Attack and Stroke imaging protocol, each patient’s
case is discussed in a multidisciplinary setting including the
cerebrovascular and endovascular teams, and the best treatment option, whether microsurgical or endovascular is considered. The authors nicely describe their experience with
intracranial bypass procedures and their results compare favorably with previous work.2-4 We should add that extracranial revascularization procedures are also available and include vertebral-carotid transposition, bypass techniques using
interposition grafts from the subclavian or common carotid
arteries to the vertebral artery and endarterectomy of the
vertebral artery or subclavian artery,5 all of which may be considered for the microsurgical management of low-flow vertebrobasilar disease.
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American Academy of Neurology Guidelines
and the Neurologic Determination of Death
To the Editor Greer et al1 analyzed compliance of hospital protocols on brain death (BD) determination with the 2010 American Academy of Neurology (AAN) guidelines. They posited that
this neurologic standard is 100% accurate. We comment on the
accuracy claim.
First, accuracy is judged by resumption of a specific set
of ceased neurologic functions within a predefined short
timeline. Longer waiting times negatively affect organ
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donation. However, the irreversibility timeline of BD findings has not been scientifically established. The eventual
outcome is terminal organ procurement or treatment withdrawal, but, although resulting in a 100% death rate, inherently confounds the reported accuracy or false-positive rate.
Indeed, false-positive cases are generally reported when
court orders support families’ request for prolonged lifesupport treatment. The McMath 2 and Hailu 3 cases are
examples.
Second, for a similar severity of brain injuries, the AAN
standard is 370% more likely to diagnose BD than other more
stringent worldwide guidelines.4 The almost 4-fold increase
implicitly challenges the standard’s accuracy. A normal or minimally ischemic brainstem was reported by histopathology at
autopsy in 60% of donors who were determined dead by the
AAN standard.5
Third, the accepted medical standard must comply
with the legal standard. 1 The Supreme Court of Nevada 3
opined in 2015: “Although ‘it is for [the] law to define the
standard of death,’ courts have deferred to the medical community to determine the applicable criteria for deciding
whether brain death is present” and “though courts defer to
the medical community to determine the applicable
criteria to measure brain functioning, it is the duty of the
law to establish the applicable standard that said criteria
must meet.”
The AAN standard requires confirming unresponsiveness (equated with coma) and absent motor brainstem
reflexes including respiration. It excludes other residual
brain functions present in BD. The Supreme Court of
Nevada3 has clarified this issue: “Are the AAN guidelines
considered ‘accepted medical standards,’ which adequately
measure all functions of a person’s entire brain, including
the brain stem?... Based on the foregoing, and the record
before us, we are not convinced that the AAN guidelines are
considered the accepted medical standard that can be
applied in a way to make Nevada’s Determination of Death
Act uniform with states that have adopted it, as the
[Uniform Determination of Death Act] requires.”
We posit that the AAN standard describes severe neurologic disabilities not equivalent with biologic death, but instead fall within the spectrum of disorders of consciousness.
Research is needed to characterize this neurologic state and
validate a reversibility timeline.
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In Reply Rady and Verheijde appear to have missed the point
of our article1 or otherwise have chosen to use it as a platform
to criticize the American Academy of Neurology Practice Parameters (AANPPs). Our study was designed to look at variability of US hospital policies in comparison with the AANPPs,
which are rather uniformly considered the standard document in the United States. Indeed, to our knowledge, there is
no position statement from another US society, or any document from another country, that is used as an example to
construct hospital policies in the United States.
Our original study in 2008 demonstrated concerning variability in hospital policies in comparison with the 1995
AANPPs,2 which is what led us to update the parameters in
2010.3 The goals of that update were multiple: (1) to provide
an evidence-based review of the literature on brain death since
the 1995 parameters, including the important finding that there
had been no legitimate reports of inaccurate determination of
death using those criteria; (2) to provide a minimum standard for brain death determination, which was, in fact, far more
detailed and proscriptive than the 1995 parameters; and (3) to
provide a comprehensive and detailed explanation for how
brain death should be determined in a meticulous and highly
careful manner, ensuring a conservative approach and that patients would not be determined dead if there was any concern for confounding or inaccuracy. Our hope was that US hospitals would readily change their local policies to ensure a
highly stringent and accurate approach.
Rady and Verheijde have chosen to distract from the goals
and findings of our study, and their letter is nothing but a straw
man argument. First, there are no legitimate or objectively confirmed cases of erroneous brain death determination in the
medical literature. Second, they suggest that there must be histopathological confirmation of death of all brain cells. However, according to the Uniform Determination of Death Act,4
there must be irreversible cessation of function of the entire
brain. Brain death is a clinical diagnosis; there is no requirement for, or practicality to, requiring a pathological confirmation. Third, the Nevada Supreme Court inexplicably ruled that
the AANPPs might not be “accepted medical standards” as
stipulated by the Uniform Determination of Death Act. The
AANPPs from 2010 most certainly do appropriately and thoroughly measure the function of the entire brain. Ancillary tests
do not measure brain function, are subject to false-positives
and false-negatives,5 and are not necessary if the clinical evaluation (including the exclusion of possible confounders) is done
correctly. No ancillary testing to date has improved (and
thereby questioned) prior methods of clinical diagnosis.6

The 2010 AANPPs remain the authoritative statement, have
been heavily vetted, and provide overtly stringent instructions on brain death determination. Efforts should be made to
ensure widespread hospital adoption of the more stringent
standards as outlined in that work, which is the only proper
conclusion of our study.1
David M. Greer, MD, MA
Panayiotis N. Varelas, MD, PhD
Eelco F. M. Wijdicks, MD, PhD
Author Affiliations: Department of Neurology, Yale University School of
Medicine, New Haven, Connecticut (Greer); Department of Neurology, Henry
Ford Hospital, Detroit, Michigan (Varelas); Department of Neurology, Mayo
Clinic, Rochester, Minnesota (Wijdicks).
Corresponding Author: David M. Greer, MD, MA, Department of Neurology,
Yale University School of Medicine, 15 York St, Mailstop LLCI 912, New Haven,
CT 06520 (david.greer@yale.edu).
Published Online: April 11, 2016. doi:10.1001/jamaneurol.2016.0431.
Conflict of Interest Disclosures: None reported.
1. Greer DM, Wang HH, Robinson JD, Varelas PN, Henderson GV, Wijdicks EM.
Variability of brain death policies in the United States. JAMA Neurol. 2016;73(2):
213-218.
2. The Quality Standards Subcommittee of the American Academy of
Neurology. Practice parameters for determining brain death in adults (summary
statement). Neurology. 1995;45(5):1012-1014.
3. Wijdicks EF, Varelas PN, Gronseth GS, Greer DM; American Academy of
Neurology. Evidence-based guideline update: determining brain death in adults:
report of the Quality Standards Subcommittee of the American Academy of
Neurology. Neurology. 2010;74(23):1911-1918.
4. Uniform Determination of Death Act, 12 uniform laws annotated 589 (West
1993 and West suppl 1997).
5. Busl KM, Greer DM. Pitfalls in the diagnosis of brain death. Neurocrit Care.
2009;11(2):276-287.
6. Wijdicks EFM. Brain Death. 2nd ed. Oxford, England: Oxford University Press;
2011.

Olfactory Loss—On the Road to Potential Diagnosis
Criteria of Alzheimer Disease
To the Editor Rosebud and colleagues1 reported on a longitudinal study strengthening the idea that olfactory impairment has
potential to be a biomarker for diagnosing mild cognitive impairment (MCI) and Alzheimer disease (AD) or early detection for cognitively normal elderly individuals who would likely
progress to MCI or AD. The underlying mechanism may be due
to, at least in part, the involvement of AD neuropathological
processes in both the olfactory bulb and other cerebral areas
that are related to olfactory function.
One study2 even pointed out that olfactory deficit, in terms
of the prediction of cognitive decline in cognitively normal individuals, was superior to impairment in episodic memory,
which is one of the earliest cognitive symptoms and has an excellent specificity for AD. However, olfactory impairment is not
very specific to AD; it is also a common feature of other neurodegenerative diseases, including Parkinson disease (PD), dementia with Lewy bodies, PD dementia, frontotemporal dementias, corticobasal syndromes, and progressive supranuclear
palsy. As for PD, the prevalence of olfactory impairment is more
than 90% and appears to exceed the prevalence of other cardinal motor signs.3 The sensitivity and specificity of olfactory testing in discriminating PD from non-PD is consider-
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